Skip to main content
Top

06-09-2024 | Type 2 Diabetes | Article

Lifetime history of gestational diabetes and cognitive function in parous women in midlife

Authors: Diana C. Soria-Contreras, Siwen Wang, Jiaxuan Liu, Rebecca B. Lawn, Makiko Mitsunami, Alexandra C. Purdue-Smithe, Cuilin Zhang, Emily Oken, Jorge E. Chavarro

Published in: Diabetologia

Login to get access

Abstract

Aims/hypothesis

We aimed to determine whether a history of gestational diabetes mellitus (GDM) is associated with cognitive function in midlife.

Methods

We conducted a secondary data analysis of the prospective Nurses’ Health Study II. From 1989 to 2001, and then in 2009, participants reported their history of GDM. A subset participated in a cognition sub-study in 2014–2019 (wave 1) or 2018–2022 (wave 2). We included 15,906 parous participants (≥1 birth at ≥18 years) who completed a cognitive assessment and were free of CVD, cancer and diabetes before their first birth. The primary exposure was a history of GDM. Additionally, we studied exposure to GDM and subsequent type 2 diabetes mellitus (neither GDM nor type 2 diabetes, GDM only, type 2 diabetes only or GDM followed by type 2 diabetes) and conducted mediation analysis by type 2 diabetes. The outcomes were composite z scores measuring psychomotor speed/attention, learning/working memory and global cognition obtained with the Cogstate brief battery. Mean differences (β and 95% CI) in cognitive function by GDM were estimated using linear regression.

Results

The 15,906 participants were a mean of 62.0 years (SD 4.9) at cognitive assessment, and 4.7% (n=749) had a history of GDM. In models adjusted for age at cognitive assessment, race and ethnicity, education, wave of enrolment in the cognition sub-study, socioeconomic status and pre-pregnancy characteristics, women with a history of GDM had lower performance in psychomotor speed/attention (β −0.08; 95% CI −0.14, −0.01) and global cognition (β −0.06; 95% CI −0.11, −0.01) than those without a history of GDM. The lower cognitive performance in women with GDM was only partially explained by the development of type 2 diabetes.

Conclusions/interpretation

Women with a history of GDM had poorer cognition than those without GDM. If replicated, our findings support future research on early risk modification strategies for women with a history of GDM as a potential avenue to decrease their risk of cognitive impairment.

Graphical Abstract

Appendix
Available only for authorised users
Literature
10.
go back to reference Zlokovic BV, Gottesman RF, Bernstein KE et al (2020) Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimers Dement 16(12):1714–1733. https://doi.org/10.1002/alz.12157CrossRefPubMed Zlokovic BV, Gottesman RF, Bernstein KE et al (2020) Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimers Dement 16(12):1714–1733. https://​doi.​org/​10.​1002/​alz.​12157CrossRefPubMed
18.
Metadata
Title
Lifetime history of gestational diabetes and cognitive function in parous women in midlife
Authors
Diana C. Soria-Contreras
Siwen Wang
Jiaxuan Liu
Rebecca B. Lawn
Makiko Mitsunami
Alexandra C. Purdue-Smithe
Cuilin Zhang
Emily Oken
Jorge E. Chavarro
Publication date
06-09-2024
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-024-06270-w

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more